Prospective validation of the prognostic 31‐gene expression profiling test in primary cutaneous melanoma

BACKGROUND: Gene expression profiling (GEP) has been integrated into cancer treatment decision‐making in multiple neoplasms. We prospectively evaluated the prognostic utility of the 31‐GEP test (DecisionDx‐Melanoma, Castle Biosciences, Inc) in cutaneous melanoma (CM) patients undergoing sentinel nod...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Keller, Jennifer, Schwartz, Theresa L., Lizalek, Jason M., Chang, Ea‐sle, Patel, Ashaki D., Hurley, Maria Y., Hsueh, Eddy C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2019
Soggetti:
Clinical Cancer Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6536922/
https://ncbi.nlm.nih.gov/pubmed/30950242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2128
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi